Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: Implications for oxygen sensing

Cell Growth and Differentiation

Volumn 12, Issue 9, 2001, Pages 447-455

  Yang, H ^a   Kaelin W G , Jr ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE; EXTRACELLULAR MATRIX; GENE CONTROL; GENOTYPE; HUMAN; HYPOXIA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; VON HIPPEL LINDAU DISEASE;

ANIMALS; ANOXIA; CELL CYCLE; CELL CYCLE PROTEINS; CULLIN PROTEINS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; GENOTYPE; HIPPEL-LINDAU DISEASE; HUMANS; LIGASES; NEOPLASMS; OXYGEN; PHENOTYPE; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0034794158     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes)
2. Ueber eine sehr seltene erkrankung der nethaut
3. Zur frage der angiomatosis retinae und ihrer hirncomplikation
4. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease
5. Confirmation of linkage in von Hippel-Lindau disease
6. Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localization of the VHL locus
7. Specific genetic change in tumors associated with von-Hippel-Lindau disease
8. Von-Hippel Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma
9. Specific genetic change in tumors associated with von Hippel-Lindau disease
10. Localization of the gene for von Hippel-Lindau disease to a small region of chromosome 3p by genetic linkage analysis
11. Identification of the von Hippel-Lindau disease tumor suppressor gene
12. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
13. Somatic mosaicism in von Hippel-Lindau disease
14. Mosaicism in von Hippel-Lindau disease: Lessons from kindreds with germline mutations identified in offspring with mosaic parents
15. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients
16. Von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease
17. A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions < 1mm in size
18. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens
19. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma
20. Lessons from hereditary colorectal cancer
21. Cancer-susceptibility genes. Gatekeepers and caretakers
22. Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer
23. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas
24. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in non-familial clear cell renal carcinoma
25. Germ-line mutations in the von Hippel-Lindau tumor suppressor gene are similar to somatic von Hippel-Lindau abberations in sporadic renal cell carcinoma
26. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal tumourigenesis
27. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous systems hemangioblastomas
28. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas
29. Mutations of the VHL tumour suppressor gene in renal carcinoma
30. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
31. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation
32. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal cell carcinoma
33. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma
34. Tumor suppression by the human von Hippel-Lindau gene product
35. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene
36. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
37. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling
38. Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1
39. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function
40. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan
41. Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumor suppressor gene
42. Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene
43. Expression pattern of the von Hippel-Lindau protein in human tissues
44. Von Hippel-Lindau tumor suppressor gene. Localization of expression by in situ hybridization
45. Expression of the von Hippel-Lindau disease tumor suppressor gene during human embryogenesis
46. Expression of the von Hippel-Lindau tumor-suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis
47. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation
48. Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity
49. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor
50. Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues
51. Characterization of the VHL tumor suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations
52. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density
53. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein
54. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region
55. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent
56. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2
57. Role of exon 2-encoded β-domain of the von Hippel-Lindau tumor suppressor protein
58. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
59. Expression of growth factors and growth factor receptors in capillary hemangioblastoma
60. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α
61. Retinal hemangioblastoma. A histologic, immunohistochemical, and ultrastructural evaluation
62. Expression of vascular endothelial growth factor in capillary hemangioblastoma
63. Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene
64. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas
65. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
66. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors
67. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
68. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma
69. Polycythemia: Mzechanisms and management
70. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein
71. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumor suppressor gene product
72. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein
73. The von Hippel-Lindau gene product is necessary for oxygen-dependent proteolysis of hypoxia-inducible factor α subunits
74. Inhibition of transcriptional elongation by the VHL tumor suppressor protein
75. The von Hippel-Lindau tumorsuppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins
76. Studying interactions of four proteins in the yeast two-hybrid system: Structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein
77. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C
78. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau protein requires binding to complexes containing elongins B/C and Cul2
79. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase
80. Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations
81. Elongin (SIII). A multisubunit regulator of elongation by RNA polymerase II
82. The elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families
83. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box
84. Cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family
85. Cdc53p acts in concert with Cdc4p and Cdc34p to control the G1-to-S-phase transition and identifies a conserved family of proteins
86. Cdc53 targets phosphorylated G1 cyclins for degradation by the ubiquitin proteolytic pathway
87. SCF and Cullin/Ring H2-based ubiquitin ligases
88. Structure of the VHL-elonginC-elonginB complex: Implications for VHL tumor suppressor function
89. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity
90. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex
91. HIF-1 and human disease: One highly involved factor
92. Regulation of mammalian 02 homeostasis by hypoxiainducible factor 1
93. Oxygen sensing and signaling: Impact on the regulation of physiologically important genes
94. Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein β domain
95. Activation of HIF1a ubiquitination by a reconstituted von Hippel-Lindau tumor suppressor complex
96. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein
97. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein
98. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein
99. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel-Lindau disease
100. Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF
101. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing
102. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
103. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor α (HIF-α) proteins
104. Prolyl 4-hydroxylases and their protein disulfide isomerase subunit
105. Identification of a novel proline-rich peptide-binding domain in prolyl 4-hydroxylase
106. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix
107. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells
108. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
109. Role of transforming growth factor-α in VHL-/- clear cell renal carcinoma cell proliferation: A possible mechanism coupling von Hippel-Lindau tumor suppressor inactivation and tumorigenesis
110. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor
111. Coexpression of transforming growth factor-α and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system
112. Differential response to transforming growth factor (TGF)-α and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types
113. Mitogenic effects of EGF/TGF alpha and immunolocalization of cognate receptors in human fetal kidneys
114. Growth regulation of human renal carcinoma cells: Role of transforming growth factor α
115. Effects of transforming growth factor-β, transforming growth factor-α, and other growth factors on renal proximal tubule cells
116. Modulation of pro-epidermal growth factor, pro-transforming growth factor α and epidermal growth factor receptor gene expression in human renal carcinomas
117. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila
118. Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity
119. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: Implications for the potential organization of the human von Hippel-Lindau disease gene
120. Comparative sequence analysis of the VHL tumor suppressor gene
121. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice
122. Hypoxiahuman placental development
123. Expression, ontogeny, and regulation of hypoxia-inducible transcription factors in the human placenta
124. Placental cell fates are regulated in vivo by HIF-mediated hypoxia responses
125. Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro
126. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor
127. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas
128. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function
129. Renal cysts, renal cancer and von Hippel-Lindau disease
130. Autosomal dominant polycystic kidney disease: Molecular analysis
131. Biology of disease: Biology of polycystic kidney disease
132. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumor suppressor gene in sporadic and syndromic phaeochromocytomas